Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06678074 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
A Phase 1 study of STEMI and STEMI (ST Elevation MI), sponsored by Implicit Bioscience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06678074 is a Phase 1 study of STEMI and STEMI (ST Elevation MI) that is actively recruiting participants, run by Implicit Bioscience. The registered enrollment target is 10 participants, below the 1,739-participant average among 4 other STEMI trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06678074, a Phase 1 study of STEMI and STEMI (ST Elevation MI), is actively recruiting participants, sponsored by Implicit Bioscience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).
Conditions Studied
Interventions
- DRUG Atibuclimab (IC14), 20 mg/kg intravenously, once
- OTHER Placebo, 150 mL intravenously, once
Study Locations (2)
Missouri
- Washington University School of Medicine - St Louis
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06678074
The ClinicalTrials.gov registry entry for NCT06678074 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,739-participant average among 4 other STEMI trials with a reported enrollment target (99% lower). The listed sponsor is Implicit Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with STEMI appearing as the primary indexed condition, and to 2 interventions - of which Atibuclimab (IC14), 20 mg/kg intravenously, once is the first listed.
NCT06678074 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Virginia.
Frequently Asked Questions
What is clinical trial NCT06678074 about?
NCT06678074 is a clinical study titled "Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI". Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammat...
What is the current status of trial NCT06678074?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-02-06. Estimated completion is 2026-09-01.
What conditions does trial NCT06678074 study?
This clinical trial studies the following conditions: STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation.
What interventions are being tested in trial NCT06678074?
The interventions under investigation include: Atibuclimab (IC14), 20 mg/kg intravenously, once (DRUG), Placebo, 150 mL intravenously, once (OTHER).
Who is sponsoring clinical trial NCT06678074?
This trial is sponsored by Implicit Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06678074 being conducted?
This trial has 2 study locations across Missouri, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for STEMI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
RECRUITING · NA
-
Intraoperative Echocardiography in Low-Risk CABG Surgery
ACTIVE NOT RECRUITING · NA
-
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
COMPLETED
-
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.